Loading Pathway...
Error: Pathway image not found.
Hide
Pathway Description
Turoctocog Alfa Action Pathway
Homo sapiens
Drug Action Pathway
Turoctocog alfa is a recombinant factor VIII, also known as Novoeight and Zonovate, used to treat bleeding in patients with haemophilia A which is a congenital factor VIII deficiency. It is administered intravenously and acts similarly to coagulation factor VIII, forming a complex with IX in order to activate factor X leading to a blood clot forming. Turoctocog alfa allows the missing factor coagulation VIII to be replaced and restore blood clotting.
References
Turoctocog Alfa Pathway References
Ezban M, Vad K, Kjalke M: Turoctocog alfa (NovoEight(R))--from design to clinical proof of concept. Eur J Haematol. 2014 Nov;93(5):369-76. doi: 10.1111/ejh.12366. Epub 2014 May 28.
Pubmed: 24797664
Salen P, Babiker HM: Hemophilia A.
Pubmed: 29261993
Agerso H, Stennicke HR, Pelzer H, Olsen EN, Merricks EP, Defriess NA, Nichols TC, Ezban M: Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8-GP in haemophilia A dogs. Haemophilia. 2012 Nov;18(6):941-7. doi: 10.1111/j.1365-2516.2012.02896.x. Epub 2012 Jul 20.
Pubmed: 22812621
Highlighted elements will appear in red.
Highlight Compounds
Highlight Proteins
Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.
Visualize Compound Data
Visualize Protein Data
Downloads
Settings